US Patent

US11547758 — Pre-mixed, ready-to-use pharmaceutical compositions

Method of Use · Assigned to EKR THERAPEUTICS LLC · Expires 2027-04-18 · 1y remaining

Vulnerability score 88/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects pre-mixed, ready-to-use pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt for treating cardiovascular and cerebrovascular conditions.

USPTO Abstract

Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1029 — nicardipine-hydrochloride
U-1029 — nicardipine-hydrochloride
U-1029 — nicardipine-hydrochloride

Patent Metadata

Patent number
US11547758
Jurisdiction
US
Classification
Method of Use
Expires
2027-04-18
Drug substance claim
No
Drug product claim
No
Assignee
EKR THERAPEUTICS LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.